Open-Label, Randomized Study to Evaluate the Influence on the Hormonal and Ovarian Activity of Two Different Dosages of Drospirenone (either 4.0 mg for 24 Days or 2.8 mg Daily for 28 Days) Over Two Treatment Cycles in 50 Healthy, Young Females

Trial Profile

Open-Label, Randomized Study to Evaluate the Influence on the Hormonal and Ovarian Activity of Two Different Dosages of Drospirenone (either 4.0 mg for 24 Days or 2.8 mg Daily for 28 Days) Over Two Treatment Cycles in 50 Healthy, Young Females

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2012

At a glance

  • Drugs Drospirenone (Primary)
  • Indications Pregnancy
  • Focus Pharmacodynamics
  • Sponsors Leon Farma
  • Most Recent Events

    • 26 May 2012 Actual end date 17 Apr 2012 added as reported by European Clinical Trials Database.
    • 26 May 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 18 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top